The advantage of women in cancer survival: An analysis of EUROCARE-4 data

A. Micheli, R. Ciampichini, W. Oberaigner, L. Ciccolallo, E. de Vries, I. Izarzugaza, P. Zambon, G. Gatta, R. De Angelis

Research output: Contribution to journalArticle

Abstract

We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer.

Original languageEnglish
Pages (from-to)1017-1027
Number of pages11
JournalEuropean Journal of Cancer
Volume45
Issue number6
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Survival Analysis
Neoplasms
Aptitude
Survival
Pleura
Thyroid Diseases
Gonadal Steroid Hormones
Biliary Tract
Salivary Glands
Multiple Myeloma
Hodgkin Disease
Rectum
Non-Hodgkin's Lymphoma
Esophagus
Pancreas
Melanoma
Stomach
Colon
Leukemia
Urinary Bladder

Keywords

  • Cancer survival
  • EUROCARE
  • Gender differences
  • Sex hormones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., ... De Angelis, R. (2009). The advantage of women in cancer survival: An analysis of EUROCARE-4 data. European Journal of Cancer, 45(6), 1017-1027. https://doi.org/10.1016/j.ejca.2008.11.008

The advantage of women in cancer survival : An analysis of EUROCARE-4 data. / Micheli, A.; Ciampichini, R.; Oberaigner, W.; Ciccolallo, L.; de Vries, E.; Izarzugaza, I.; Zambon, P.; Gatta, G.; De Angelis, R.

In: European Journal of Cancer, Vol. 45, No. 6, 04.2009, p. 1017-1027.

Research output: Contribution to journalArticle

Micheli, A, Ciampichini, R, Oberaigner, W, Ciccolallo, L, de Vries, E, Izarzugaza, I, Zambon, P, Gatta, G & De Angelis, R 2009, 'The advantage of women in cancer survival: An analysis of EUROCARE-4 data', European Journal of Cancer, vol. 45, no. 6, pp. 1017-1027. https://doi.org/10.1016/j.ejca.2008.11.008
Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I et al. The advantage of women in cancer survival: An analysis of EUROCARE-4 data. European Journal of Cancer. 2009 Apr;45(6):1017-1027. https://doi.org/10.1016/j.ejca.2008.11.008
Micheli, A. ; Ciampichini, R. ; Oberaigner, W. ; Ciccolallo, L. ; de Vries, E. ; Izarzugaza, I. ; Zambon, P. ; Gatta, G. ; De Angelis, R. / The advantage of women in cancer survival : An analysis of EUROCARE-4 data. In: European Journal of Cancer. 2009 ; Vol. 45, No. 6. pp. 1017-1027.
@article{7de27542c31445be87ffbc35b636fd17,
title = "The advantage of women in cancer survival: An analysis of EUROCARE-4 data",
abstract = "We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5{\%} lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer.",
keywords = "Cancer survival, EUROCARE, Gender differences, Sex hormones",
author = "A. Micheli and R. Ciampichini and W. Oberaigner and L. Ciccolallo and {de Vries}, E. and I. Izarzugaza and P. Zambon and G. Gatta and {De Angelis}, R.",
year = "2009",
month = "4",
doi = "10.1016/j.ejca.2008.11.008",
language = "English",
volume = "45",
pages = "1017--1027",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "6",

}

TY - JOUR

T1 - The advantage of women in cancer survival

T2 - An analysis of EUROCARE-4 data

AU - Micheli, A.

AU - Ciampichini, R.

AU - Oberaigner, W.

AU - Ciccolallo, L.

AU - de Vries, E.

AU - Izarzugaza, I.

AU - Zambon, P.

AU - Gatta, G.

AU - De Angelis, R.

PY - 2009/4

Y1 - 2009/4

N2 - We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer.

AB - We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer.

KW - Cancer survival

KW - EUROCARE

KW - Gender differences

KW - Sex hormones

UR - http://www.scopus.com/inward/record.url?scp=62549095873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549095873&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2008.11.008

DO - 10.1016/j.ejca.2008.11.008

M3 - Article

C2 - 19109009

AN - SCOPUS:62549095873

VL - 45

SP - 1017

EP - 1027

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -